Stock Events

Stock Events

Neuren Pharmaceuticals 

$13.76
50
-$0.24-1.71%Friday 14:36

Statistics

Day High
14
Day Low
14
52W High
17.25
52W Low
7.7
Volume
6,217
Avg. Volume
565
Mkt Cap
1.74B
P/E Ratio
84.13
Dividend Yield
1.51%
Dividend
0.21

Upcoming

Dividends

1.51%Dividend Yield
Oct 2026
$0.10
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

Aug 24Expected
Q3 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
0.01
0.35
0.69
1.03
Expected EPS
0.08616004759107755
Actual EPS
0.03686063771764213

Financials

47.24%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
38.15MRevenue
18.02MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NURPF. It's not an investment recommendation.
NVIDIA
9
NVDA
Fortescue
8
FMG.AU
CSL
8
CSL.AU
Telix Pharmaceuticals
8
TLX.AU

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.55B
Acadia Pharmaceuticals targets central nervous system disorders, including rare diseases, similar to Neuren's therapeutic areas.
Biogen
BIIB
Mkt Cap37.49B
Biogen focuses on neurodegenerative diseases, multiple sclerosis, and spinal muscular atrophy, competing in the neurological space with Neuren.
PTC Therapeutics
PTCT
Mkt Cap5.01B
PTC Therapeutics works on rare disorders, including neurological diseases, making it a direct competitor to Neuren.
Ionis Pharmaceuticals
IONS
Mkt Cap7.23B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery for neurological diseases, competing with Neuren's focus.
Alnylam Pharmaceuticals
ALNY
Mkt Cap22.1B
Alnylam Pharmaceuticals develops RNAi therapeutics for neurological disorders, directly competing with Neuren's research focus.
Anavex Life Sciences
AVXL
Mkt Cap110.31M
Anavex Life Sciences focuses on neurodegenerative and neurological diseases, including Rett syndrome, a key area for Neuren.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics is engaged in gene editing for various diseases, including potential treatments for neurological disorders, posing indirect competition to Neuren.

About

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Show More
CEO
Jonathan Charles Pilcher
Employees
9
Country
Australia
ISIN
NZNEUE0001S8
WKN
000A0DPHQ

Listings

STU
DE
NK9.STU
OTC Link
US
NURPF
AU
AU
NEU.AU
F
DE
NK9.F

0 Comments

Share your thoughts

FAQs

What is Neuren Pharmaceuticals stock price today?▼
The current price of NURPF is $13.76 USD — it has decreased by -1.71% in the past 24 hours. Watch Neuren Pharmaceuticals stock price performance more closely on the chart.
What is Neuren Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Neuren Pharmaceuticals stocks are traded under the ticker NURPF.
Is Neuren Pharmaceuticals stock price growing?▼
NURPF stock has fallen by -3.62% compared to the previous week, the month change is a -3.62% fall, over the last year Neuren Pharmaceuticals has showed a +6.58% increase.
What is Neuren Pharmaceuticals market cap?▼
Today Neuren Pharmaceuticals has the market capitalization of 1.74B
When is the next Neuren Pharmaceuticals earnings date?▼
Neuren Pharmaceuticals is going to release the next earnings report on February 24, 2027.
What were Neuren Pharmaceuticals earnings last quarter?▼
NURPF earnings for the last quarter are 0.03 USD per share, whereas the estimation was 0.06 USD resulting in a -57.22% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Neuren Pharmaceuticals revenue for the last year?▼
Neuren Pharmaceuticals revenue for the last year amounts to 38.15M USD.
What is Neuren Pharmaceuticals net income for the last year?▼
NURPF net income for the last year is 18.02M USD.
Does Neuren Pharmaceuticals pay dividends?▼
Yes, NURPF dividends are paid semi-annual. The last dividend per share was 0.1 . As of today, Dividend Yield (FWD)% is 1.51%.
How many employees does Neuren Pharmaceuticals have?▼
As of November 8, 2026, the company has 9 employees.
In which sector is Neuren Pharmaceuticals located?▼
Neuren Pharmaceuticals operates in the Health & Wellness sector.
When did Neuren Pharmaceuticals complete a stock split?▼
The last stock split for Neuren Pharmaceuticals was on November 21, 2017 with a ratio of 1:20.
Where is Neuren Pharmaceuticals headquartered?▼
Neuren Pharmaceuticals is headquartered in Hawthorn East, Australia.